Cleerly ISCHEMIA vs AI-ECG Tracker
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, leveraging CCTA scans to determine vessel-level ischemia likelihood and characterize plaque. This tool is ideal for detailed diagnosis and personalized treatment planning, offering insights into stenosis severity and 3D arterial models.
View Cleerly ISCHEMIA →Choose AI-ECG Tracker if…
Choose AI-ECG Tracker if your primary need is rapid, high-accuracy automated diagnosis of a broad spectrum of cardiac abnormalities from 12-lead ECG data. This tool is best suited for scenarios demanding quick initial screening and interpretation of conditions like arrhythmias, myocardial ischemia, and infarction, with results available in approximately 3 seconds.
View AI-ECG Tracker →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | AI-ECG Tracker |
|---|---|---|
| Pricing | Contact for details | Unknown |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Mobile app, intended for use by qualified healthcare professionals in hospitals and other healthcare facilities. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIATool A emphasizes a fully web-based platform with interactive reports and API integration, which generally offers a more modern and streamlined user experience. This facilitates easier access and integration into existing clinical workflows compared to Tool B's mix of on-premise and desktop client components.
Clinical Value
Cleerly ISCHEMIATool A provides a more in-depth and comprehensive assessment of coronary artery disease by analyzing CCTA scans for non-invasive FFR estimation, detailed plaque characterization, and 3D models. This offers advanced insights for personalized diagnosis and treatment planning, moving beyond the more preliminary diagnostic capabilities of ECG analysis offered by Tool B.
Pricing & Value
Cleerly ISCHEMIABoth tools lack public pricing transparency, making a direct value comparison difficult. However, Tool A provides slightly more context by stating that pricing varies by provider and that its proxy service is included without additional charge, offering a marginally clearer picture of its cost structure than Tool B's complete lack of public information.
Enterprise Readiness
Cleerly ISCHEMIATool A explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. Its web-based deployment with API integration also suggests easier enterprise-wide deployment and integration into existing IT infrastructure. Tool B's compliance claims are only 'likely' and not explicitly stated for the product.
Innovation
Cleerly ISCHEMIATool A demonstrates greater innovation by applying AI to CCTA for non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization, offering a more advanced and comprehensive assessment of coronary artery disease. This represents a significant leap in non-invasive cardiac diagnostics beyond the more established application of AI in ECG interpretation by Tool B.
Support & Docs
Cleerly ISCHEMIATool A provides a more clearly defined and accessible support channel specifically for existing software users, including a dedicated client support form and stated availability hours. While Tool B offers general company contact information and some product documentation, it lacks the explicit software-specific client support structure seen with Tool A.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | AI-ECG Tracker |
|---|---|---|
| Product Name | Cleerly ISCHEMIA | AI-ECG Tracker |
| Company | Cleerly | Shenzhen Carewell Electronics Co. |
| Primary Function | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Applies artificial intelligence technology to ECG auto-diagnosis, distributing innovative AI medical devices. |
| Key Analysis Method/Input | AI-enabled CCTA analysis | AI-powered ECG auto-analysis (supports 12-lead ECG data collection) |
| Key Output/Diagnosis | Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries, Comprehensive interactive web-based reports. | AI-powered ECG auto-analysis and diagnosis for common cardiac abnormalities (including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction), Rapid diagnosis in approximately 3 seconds, Comprehensive diagnosis support for 16 cardiac classifications and 104 ECG diagnostic classifications. |
| Specialties | Cardiology, Radiology | Cardiology, Emergency Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and AI-ECG Tracker.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or AI-ECG Tracker
Backers
Who funded each tool's parent company.